Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

Other than the termination of the M511 program, the most consequential info from the CC was the cash-usage projections for the rest of 2014 and the announcement of an “R&D Day” webcast in the fall, at which time additional disclosures will be made concerning the FoB pipeline. (MNTA presumably hopes the R&D Day event can be scheduled after obtaining FDA approval for Copaxone, but it will be held sometime in the fall regardless.)

I’ll post in detail about MNTA’s cash balance and 2014 cash-usage projection soon.